AstraZeneca’s experimental oral GLP-1 drug elecoglipron produced substantial reductions in body weight and blood sugar in a phase 2b trial, offering another noninjectable option in the expanding class of GLP-1 therapies for type 2 diabetes and obesity.
Key results
– In the 26-week SOLSTICE randomized, placebo-controlled study, 406 adults with type 2 diabetes across nine countries received varying starting, escalation, and maintenance doses of elecoglipron or placebo.
– Participants taking elecoglipron lost an average of 10.5% of body weight at 26 weeks; 72% of treated participants lost at least 5% of their weight.
– Nearly 90% of people on the drug reached the standard target HbA1c of 7%, compared with about 25% on placebo.
– Reported safety and tolerability were similar to other GLP-1 medications at this stage of development.
Why this matters
GLP-1 receptor agonists were developed to lower blood glucose in type 2 diabetes but have also proven effective at suppressing appetite and promoting weight loss. Oral formulations make these benefits available to people who prefer pills to injections, and they may be easier to store and transport. Several oral GLP-1 products have reached the market in recent years, expanding treatment options for diabetes and weight management.
Experts’ perspective
Clinicians not involved with the trial called the results encouraging but cautioned that larger phase 3 studies are needed to confirm long-term safety and effectiveness. Physicians highlighted that oral GLP-1s could increase access and adherence for patients who dislike needles or who find injectables inconvenient, while noting trade-offs: oral tablets are typically taken daily, whereas some injectables are once-weekly and enter the bloodstream more directly.
What to know about GLP-1 therapy
– Benefits: GLP-1 drugs lower blood glucose, reduce appetite, support weight loss, and may have cardiovascular and metabolic benefits.
– Administration: Tablets remove the need for injections and refrigeration, but dosing frequency and absorption can differ from injectables.
– Long-term strategy: GLP-1 medications are part of a sustained treatment plan. They work best alongside lifestyle changes—regular physical activity, balanced meals focused on fiber and healthy carbohydrates, weight-management strategies, and avoidance of excess sugar and saturated fats.
– Shared decision making: Every medication has potential risks and contraindications. Patients should discuss benefits and side effects with their healthcare provider to decide if a GLP-1 is appropriate for them.
Context on type 2 diabetes
Type 2 diabetes is common and growing: tens of millions of U.S. adults live with the condition and many more have prediabetes. It arises when the body’s response to insulin is impaired or insulin production is insufficient, leading to elevated blood glucose. Symptoms can be mild at first and may include persistent hunger, excessive thirst, fatigue, frequent urination, blurry vision, and numbness in the hands or feet. Management includes medications when needed but also often relies on dietary change, regular exercise (about 30 minutes daily), and long-term weight control.
Next steps
AstraZeneca has moved elecoglipron into a phase 3 program. If larger trials confirm efficacy and safety and regulatory approval follows, elecoglipron could become another oral GLP-1 option for people with type 2 diabetes and obesity. Clinicians emphasize that new medications are a tool to support lasting lifestyle improvements—not a quick fix—and that patients should consult their healthcare providers to determine the best individualized treatment plan.